Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | What to look forward to at ASCO 2022

Parag Jasani • 30 May 2022
ASCO 2022
Chronic Lymphocytic Leukemia Leukemia

Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College Hospital, London, UK, on what he is looking forward to at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Parag Jasani

0:56
Personalizing CLL therapy in the frontline
Parag Jasani • 10 Dec 2023
1:29
NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study
Parag Jasani • 10 Dec 2023
0:58
Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL
Parag Jasani • 10 Dec 2022
0:44
The evolution of treatment for elderly patients with CLL
Parag Jasani • 10 Dec 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals